- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Standardizing Stroke Care to Improve Outcomes and Reduce Costs
Researchers at the University of Michigan Medical School have developed a map of the United States highlighting significant variation in stroke care.
Researchers at the University of Michigan Medical School have developed a quilted map of the United States highlighting the tremendous variation in stroke care in need of standardization. Published this month in the journal Stroke, the study points to the huge variation in the use of the "clotbuster" drug tissue plasminogen activator (tPA), which if administered within the first few hours of a stoke can restore blood supply to the brain. This can avoid potential disabilities and lower long-term costs of care in the patients.
The population used in the study were Medicare enrollees who had suffered from a stroke and were admitted through Emergency Rooms in one of 3436 hositals surveyed in the study between 2007 and 2010. In 20% of the geographical regions where these hospitals were located, patients did not receive tPA. Of the 844,241 admissions resulting from ischemic stroke, 3.7% of patients were administered tPA and only 0.5% received intra-arterial stroke treatment, with or without tPA.
A senior author on the study believes understanding the causes of the variation and addressing them would have a significant impact on stroke-associated disability.
Read more on EurekAlert!
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
